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Background: The T-helper 17 (Th17) cells have a prominent role in inflammation as well 
as in bone and join destruction in both rheumatoid and psoriatic arthritis (RA and PsA). 
Here, we studied Th17 cell differentiation in RA and PsA.
Methods: Blood samples from healthy donors, RA and PsA patients were collected. 
CD45RO− (naive) and CD45RO+ (memory) T cells were isolated from peripherial blood 
mononuclear cell by magnetic separation. Naive T cells were stimulated with anti-CD3, 
anti-CD28, and goat anti-mouse IgG antibodies and treated with transforming grow 
factor beta, interleukin (IL)-6, IL-1β, and IL-23 cytokines and also with anti-IL-4 antibody. 
IL-17A and IL-22 production were measured by enzyme linked immunosorbent assay, 
RORC, and T-box 21 (TBX21) expression were analyzed by quantitative polymerase 
chain reaction and flow cytometry. C-C chemokine receptor 6 (CCR6), CCR4, and 
C-X-C motif chemokine receptor 3 expression were determined by flow cytometry. Cell 
viability was monitored by impedance-based cell analyzer (CASY-TT).
results: RORC, TBX21, CCR6, and CCR4 expression of memory T cells of healthy 
individuals (but not RA or PsA patients) were increased (p < 0.01; p < 0.001; p < 0.05; 
p  <  0.05, respectively) compared to the naive cells. Cytokine-induced IL-17A pro-
duction was different in both RA and PsA patients when compared to healthy donors 
(p = 0.0000026 and p = 0.0001047, respectively). By contrast, significant differences 
in IL-22 production were observed only between RA versus healthy or RA versus PsA 
patients (p = 0.000006; p = 0.0013454, respectively), but not between healthy donors 
versus PsA patients.
conclusion: The naive CD4 T-lymphocytes are predisposed to differentiate into Th17 cells 
and the in vitro Th17 cell differentiation is profoundly altered in both RA and PsA.
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inTrODUcTiOn
T-helper 17 (Th17) cells are the third major subpopulation in 
addition to Th1 and Th2, which was described in mice (1) and 
in human (2). They are the main producers of interleukin-17A 
(IL-17A), IL-17F, IL-22, and tumor necrosis factor alpha (TNFα) 
(2–6). Th17  cells are necessary for the physiological defense 
against extracellular bacterial and fungal infections. In addition, 
they contribute to inflammation in several autoimmune diseases, 
such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), multiple sclerosis, inflammatory bowel diseases, psoriasis, 
or psoriatic arthritis (PsA) (3–8).
The Th17-derived cytokines induce the production of nume-
rous inflammatory mediator and effector molecules, such as 
proinflammatory cytokines IL-6 and IL-1β, nitric oxide, matrix 
meta lloproteinases, granulocyte-monocyte colony-stimulating 
factor (GM-CSF), and granulocyte colony-stimulating factor 
(G-CSF). This complex effect includes neutrophil recruitment, 
osteoclastogenesis, synovial proliferation, and finally may lead to 
bone and joint destruction in RA (3–5, 7, 9–12). IL-17A and IL-22 
are co-expressed by Th17 cells and contribute to the pathologic 
events for example development of the psoriatic plaque, pannus 
formation in the joint, joint erosion, and new bone formation in 
PsA (3–7, 9–18).
Human IL-17A producing cells originate from cluster of differ-
entiation 161 (CD161)+CD4+ progenitor cells, which consti-
tutively express retinoic acid-related orphan receptor variant 2 
(RORC2) (19–21). RORC2 gene encodes the RAR-related orphan 
receptor gamma (RORγ) which is a master regulator of human 
Th17 cells (20, 22). The Th1-specific transcription factor, T-box 21 
(TBX21) encodes for the T cell-specific T-box transcription factor 
T-bet (T-bet) that regulates interferon gamma (IFNγ) production 
(23). Those IL-17A-producing cells that do not produce IFNγ, are 
characterized by the co-expression of C-C chemokine receptor 6 
(CCR6) and CCR4, while CCR6+ and C-X-C motif chemokine 
receptor 3 (CXCR3+) cells can produce IL-17A with or without 
IFNγ (2, 24). Naive CD4+ T cells may differentiate toward Th17 cells 
depending on the initial effect of cytokines, such as transforming 
grow factor beta (TGFβ), IL-1β, IL-6, IL-23 (2, 22, 25–30), and 
other regulating factors such as aryl hydrocarbon receptor 
(AHR) (31).
Interleukin-17A and IL-22 positive cells are highly repre-
sented in peripherial blood mononuclear cells (PBMCs) and 
synovial tissues of RA and in the psoriatic lesions of PsA patients. 
Furthermore, some studies showed a correlation between the 
Th17-related cytokine production and the clinical parameters in 
both diseases. IL-17A targeting biologicals are used in the clinic, 
while IL-22 is a potential therapeutic target in psoriasis and in 
inflammatory arthropathies (9–11, 13–17, 32–35).
In this study, we characterized the naive CD4+ T  cells in 
healthy individuals and patients with RA and PsA based on their 
expression of transcription factors and chemokine receptors as 
well as on their cytokine production during Th17 differentiation.
PaTienTs anD MeThODs
Patients
Patients were recruited in the rheumatology outpatient depart-
ment of the Semmelweis University (Hospital of Hospitaller 
Brothers of St. John of God, Budapest, Hungary). Patients were 
diagnosed with RA (n =  12) according to the 2010 American 
College of Rheumatology/European League Against Rheumatism 
classification criteria (36), or with PsA (n = 7) (37); all patients 
had moderate or active disease. The clinical parameters and treat-
ments of RA and PsA patients were explained in the Table S1 in 
Supplementary Material. Matched control samples were collected 
from healthy volunteers (n = 12).
cell Preparation
Peripheral blood samples were collected into EDTA vacutainer 
tubes (Greiner Bio-One). PBMCs were isolated from the blood 
of healthy volunteers, RA, and PsA patients by density gradient 
centrifugation over Histopaque-1077 (Sigma-Aldrich). For quan-
titative real-time PCR analysis, the CD4+ T cells were negatively 
isolated from PBMCs with a magnetic-activated cell sorting 
CD4+ T Cell Isolation Kit (Miltenyi Biotec), according to the 
manufacturer’s instructions. The CD45RO− (negative fractions) 
and CD45RO+ (positive fractions) cells were separated also with 
a CD45RO Microbeads (Miltenyi Biotec). For flow cytometric 
analysis of chemokine receptors, the CD4+CD45RO− cells were 
negatively isolated from PBMCs with naive CD4+ T Cell isolation 
kit (Miltenyi Biotec) according to the manufacturer’s instructions. 
The purity of the separated cells was at least 95% in all cases, as 
determined by flow cytometry.
In Vitro cell culture
The cells were cultured (106/mL) in Roswell Park Memorial 
Institute 1640 (Sigma-Aldrich) supplemented with 10% fetal 
bovine serum (Gibco), 2  mM glutamine, and 1% penicillin–
streptomycin solution (Sigma). The cells were stimulated with 
anti-CD3 (1  µg/mL) (R&D Systems), anti-CD28 (1  µg/mL) 
(BioLegend), and with F(ab′)2 fragment goat anti-mouse IgG 
(CAB) (1  µg/mL) (Jackson ImmunoResearch) antibodies, and 
treated with TGFβ (2.5 ng/mL), IL-6 (25 ng/mL), IL-1β (10 ng/mL), 
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibody; ACR, 
American College of Rheumatology; AOV, analysis of variance; CAB, 
F(ab′)2 fragment goat anti-mouse IgG; CCR6, C-C chemokine receptor 6; 
CD161, cluster of differentiation 161; cDNA, complementary deoxyribonucleic 
acid; CRP, C-reactive protein; CXCR3, C-X-C motif chemokine receptor 3; 
ELISA, enzyme linked immunosorbent assay; ESR, the erythrocyte sedimentation 
rate; EULAR, European League Against Rheumatism; FACS, fluorescence-activated 
cell sorting; FBS, fetal bovine serum; G-CSF, granulocyte colony-stimulating 
factor; GM-CSF, granulocyte-monocyte colony-stimulating factor; IBD, inflam-
matory bowel diseases; IFNγ, interferon gamma; IL-17A, interleukin-17; LDA, 
linear discriminant analysis; MACS, magnetic-activated cell sorting; MMP, matrix 
metalloproteinases; mRNA, messenger ribonucleic acid; MS, multiple sclerosis; 
NO, nitric oxide; HPRT-1, hypoxanthine phosphoribosyltransferase 1; PBMC, 
peripherial blood mononuclear cell; PsA, psoriatic arthritis; RA, rheumatoid 
arthritis; RORC2, retinoic acid-related orphan receptor variant 2; RORγ, RAR-
related orphan receptor gamma; RPMI, Roswell Park Memorial Institute; SLE, 
systemic lupus erythematosus; T-bet, T  cell-specific T-box transcription factor 
T-bet; TBX21, T-box 21; TGFβ, transforming grow factor beta; Th17, T-helper 17; 
TNFα, tumor necrosis factor alpha; Tukey HSD, Tukey’s honest significant differ-
ence test; RF, rheumatoid factor; qPCR, quantitative polymerase chain reaction.
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and IL-23 (10  ng/mL) cytokines (ImmunoTools GmbH), and 
with anti-IL-4 neutralizing antibody (10  µg/mL) (BioLegend). 
The following cytokine combination was used to promote 
Th17  cell differentiation: TGFβ +  IL-6, TGFβ +  IL-6 +  IL-1β, 
IL-1β  +  IL-23, and IL-1β  +  IL-23  +  IL-6. Anti-IL4 antibody 
was used in all cytokine combination treatments to block Th2 
development (based on a study reported by Bettelli et al. (25) and 
our unpublished data). Fifty percent of cell supernatants were 
collected on the fifth day of differentiation and the same volume 
was added, supplemented with the appropriate cytokines. The 
cells were treated for 10  days and different samples were col-
lected initially then on the 5th and 10th days for analysis. Cell 
viability was monitored by an impendance-based cell analyzer 
(CASY-TT) (Roche Innovatis AG).
Quantitative real-Time Pcr
Total RNA was isolated with NucleoSpin RNA/Protein kit 
(Macherey-Nagel) and the quantity of RNA was determined by 
NanoDrop ND-1000 spectrophotometer (NanoDrop Techno -
logies). The total amount of RNA was 1,000–4,000  ng/sample, 
which was isolated from 20,000 to 40,000 cells (there was 
no significant difference between samples from patients and 
controls). Complementary deoxyribonucleic acid (cDNA) was 
synthesized from total amount of RNA with a SensiFAST cDNA 
Synthesis Kit (Bioline) in accordance with the manufacturer’s 
instructions. The real-time PCRs were carried out in PCR Master 
Mix containing SensiFAST™ Probe Hi-ROX Kit (Bioline) using 
TaqMan assays (Thermo Fisher Scientific) for hypoxanthine 
phosphoribosyltransferase 1 (HPRT-1) (Hs02800695_m1) or 
RORC (Hs01076122_m1) or TBX21 (Hs00203436_m1) and 
25 ng cDNA per gene/well in 8 µL final volume. Specific tran-
script levels were referred to those of HPRT-1; and the ΔΔCt 
calculation method was used to determine the appropriate gene 
expressions (38).
enzyme linked immunosorbent assay 
(elisa)
Interleukin-17A and IL-22 levels were measured by human IL-17A 
and IL-22 ELISA Ready-SET-Go kits (eBioscience), according to 
the manufacturer’s protocol with the appropriate standards.
Flow cytometry
C-C chemokine receptor CCR6, CCR4, and CXCR3 expression 
of the freshly separated CD4+CD45RO−, CD4+CD45RO+, and 
the differentiated cells were measured by flow cytometry. The 
cells were centrifuged and stained in PBS containing 0.5% BSA 
for 30  min at 4°C with anti-human CCR6 FITC (BioLegend), 
anti-human CCR4 PE (BioLegend), anti-human CXCR3 PerCP 
Cy5.5 (BioLegend), and anti-human CD4 APC (BD Biosciences) 
antibodies or with the appropriate isotype controls. After wash-
ing, 5  ×  104 cells were measured with fluorescence-activated 
cell sorting (FACS) Calibur flow cytometer (BD Biosciences). 
Data were analyzed with FlowJo (Tree Star, Ashland, OR, USA). 
To determine the RORγ and T-bet expression of naive, central 
and effector memory cells, the freshly isolated PBMCs were 
permeabilized and fixed using transcription buffer set (BD 
Biosciences) according to the manufacturer’s instructions. The 
samples were stained with human naive/memory T cell ID panel 
antibody (containing anti-human CD3 APC/Cy7, anti-human 
CD4 PerCP Cy5.5, anti-human CD45RA FITC, and anti-human 
CD197 APC) (BioLegend), anti-human CD45RO PE/Cy7 
(BioLegend), anti-human T-bet PE CF597 (BD Biosciences), 
and anti-human RORγ PE (BD Biosciences) antibodies. After 
washing, 5 ×  105 cells were measured with FACS Calibur flow 
cytometer (BD Biosciences), analyzed with FlowJo (Tree Star, 
Ashland, OR, USA). Gating strategy was shown in Figure S1 in 
Supplementary Material.
statistical analysis
GraphPad Prism Software V6 (San Diego, CA, USA) was used 
for univariate statistical analyses. For the comparison of two 
dependent groups the Wilcoxon matched-pairs signed rank test, 
for two independent groups’ comparison the Mann–Whitney 
test, and for multiple group comparison the Friedman test was 
used. In case, significant differences were observed for the pair 
wise analysis, the Wilcoxon matched-pairs signed rank test or 
the Mann–Whitney test was also applied after the Friedman test. 
p-Values below 0.05 were considered as statistically significant. 
Correlation analysis was used to examine linear correlation 
between data. Using the R statistical software (39), analysis of 
variance (40) and consecutively Tukey HSD tests (41) were car-
ried out to investigate the differences in the cytokine treatment-
induced IL-17A and IL-22 production between healthy, RA, and 
PsA groups. Linear discriminant analysis (LDA) was used to 
compare and classify the healthy, RA, and PsA individuals based 
on the data regarding transcription factors, cytokine production, 
and chemokine receptor expression (42). The detailed descrip-
tion of the LDA method was summarized in the Data Sheet S1 in 
Supplementary Material.
resUlTs
The naive T cells of ra and Psa Patients 
are committed Toward Th17 and to a 
lesser extent Toward Th1 cells Based  
on Their RORC and TBX21 expression
To characterize CD4 plasticity, master regulators of the Th17 and 
Th1 engagement were measured. The CD4+CD45RO+ (memory 
Th cells/Tm) and CD4+ CD45RO− (naive Th cells) cells were iso-
lated from healthy donors, RA, and PsA patients and Th17- and 
Th1-specific transcription factors were measured by quantitative 
real-time PCR. In healthy donors, an increased messenger ribo-
nucleic acid (mRNA) expression of both the RORC and TBX21 
transcription factors were detected (6.6-fold increase, p <  0.01 
and 2-fold increase, p < 0.0001, respectively) in memory cells, as 
compared to naive cells (Figure 1A). By contrast, no significant 
difference was observed in the RORC and TBX21 expression 
between the CD45RO+ and CD45RO− cells neither in RA nor in 
PsA (Figures 1B,C).
Interestingly, while the TBX21 expression of the naive 
and memory T  cells correlated strongly (Figure  1E, r  =  0.9; 
p < 0.0001), the RORC expression did not show any correlation 
FigUre 1 | Baseline RORC and TBX21 transcription factor expression in naive and memory cells. CD4+CD45RO− naive and CD4+CD45RO+ memory T cells were 
isolated by magnetic separation from peripherial blood mononuclear cells of healthy volunteers (n = 11), rheumatoid arthritis (RA) (n = 10), and psoriatic arthritis 
(PsA) patients (n = 5). Total RNA was isolated and the gene expressions were measured by quantitative real-time PCR. Healthy donors’ (a), RA (B), and PsA 
patients’ (c) data are shown in a logarithmic scale; median, minimum, and maximum of the relative gene expression levels are indicated (Wilcoxon signed rank test 
**p < 0.01; ***p < 0.001). Correlations (Pearson correlation) are shown between the RORC (D) and TBX21 (e) expression in naive and memory T cells.
4
Baricza et al. Th17-Differentiation in Rheumatoid and PsA
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 606
(Figure  1D, r =  0.18; p =  0.17) between the two CD4+ T  cell 
subsets. These correlations (Pearson) support our main findings, 
regarding the increased RORC expression (Figure 2A; p < 0.01 
and p =  0.054, respectively) of naive T  cells in RA and PsA 
(no correlation Figure 1D), while the TBX21 expression of the 
naive cells of all patients and controls is similar (Figure 2B; strong 
correlation Figure 1E).
Intracellular flow cytometry analysis was used to character-
ize transcription factor expression levels of the individual cells 
(Figures  2A–D). The naive (CD3+CD4+CD45RO−CD45RA+ 
CD197+), effector (CD197−/Tem), and central (CD197+/Tcm) 
memory T cells (CD3+CD4+CD45RO+CD45RA−) were studied. 
Although the T-bet expression of the healthy, RA, and PsA-
derived naive cells was similar; the RORγ distribution of the RA 
and PsA samples was apparently sifted, as the cumulative images 
show (Figures  2E,F). These data confirm the increased RORγ 
expression of the naive T cells in both RA and PsA. The effector 
memory cells represent a substantial part of the memory cells 
(38.8% of the Tm cells) in all groups (without any remarkable 
difference between the patients and controls). These cells express 
RORγ or T-bet only or both T-bet and RORγ more frequently 
than the central memory T cells (Tcm cells represent 61.2% of 
FigUre 2 | Continued
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the Tm cells; p = 0.0128, p < 0.0001, and p < 0.0001, respectively, 
data not shown).
Linear discriminant analysis was performed to evaluate the 
data from naive and memory T cell-derived RORC and TBX21 
expression. The discriminative power of the healthy, RA, and PsA 
group separation was 61% and the naive T cells’ RORC expression 
had the strongest determinant role (Figure S2A in Supplementary 
Material).
chemokine receptor Pattern confirm  
the early engagement of naive T cells
To study the phenotype of T cell subsets, CCR4, CCR6, and CXCR3 
chemokine receptor expression of isolated CD4+ T  cells was 
measured by flow cytometry. Except for CXCR3, all chemokine 
receptors and their combinations had largely higher expression on 
the surface of the healthy-derived CD45RO+ memory T cells as 
compared to CD45RO− naive cells (p < 0.05 in all cases, Figure 3A; 
Figure S3A in Supplementary Material). By contrast, there was no 
significant difference between the chemokine receptor expression 
of naive and memory cells of either RA- or PsA-derived CD4+ 
T cells (Figures 3B,C; Figures S3B,C in Supplementary Material). 
These data support the premature engagement of naive T cells in 
both RA and PsA.
Naive T cells from healthy individuals, RA, and PsA patients 
were discriminated from each other with 81.3% power by the 
chemokine receptor expression data and the determinant factor 
was the proportion of the CCR4+CXCR3+ memory T cells (Figure 
S2B in Supplementary Material) by LDA analysis.
Th17 cell Differentiation Promoting 
Factors in ra and Psa
Although there is a general agreement regarding the key con-
ditions initiating the human Th17  cell differentiation, several 
different cytokine combinations were reported to promote this 
process (2, 22, 25–30). Based on previous publications and our 
experience, in addition to CD3/CD28/CAB stimulation (43) and 
anti-IL4 antibody (25), the following four cytokine combina-
tions were applied to promote naive CD4+ T cell differentiation 
to Th17: TGFβ +  IL6, TGFβ +  IL6 +  IL1β, IL1β +  IL23, and 
IL1β + IL23 + IL6.
Transcription factor (RORC and TBX21) expression and 
cytokine production (IL-17A and IL-22) were measured at the 
fifth day of the differentiation (Figures 4 and 5). At the fifth day, 
the stimulation (CD3/CD28/CAB) induced both RORC (p < 0.01) 
and TBX21 (p < 0.01) gene expression of healthy-derived T cells 
(Figure 4A). TBX21 mRNA did not change significantly neither 
in RA nor in PsA; while the RORC was upregulated in PsA 
(p < 0.05) but not in RA (Figures 4B,C).
The RORC mRNA of healthy CD4+ T cells was upregulated 
by all four cytokine combinations (p  <  0.01, in all cases) 
FigUre 2 | RORC and TBX21 expression across patient and healthy donor groups. Messenger ribonucleic acid (mRNA) expressions of RORC and TBX21 in naive 
(a,B) and memory (c,D) T cells. Gene expressions were measured by quantitative real-time PCR; the values are shown in a logarithmic scale; median, minimum, 
and maximum of the relative gene expression levels are indicated (Mann–Whitney test **p < 0.01). Flow cytometry was used to study the RAR-related orphan 
receptor gamma (RORγ) and T cell-specific T-box transcription factor T-bet (T-bet) protein levels of individual cells from healthy donors (n = 5), rheumatoid arthritis 
(RA) (n = 5), and psoriatic arthritis (PsA) (n = 5) patients. Cumulative histograms of the naive (e) and memory (F) T lymphocytes are shown.
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(Figure  4A). The RORC expression of RA T  cells was induced 
by TGFβ + IL1β + IL6 and IL1β + IL23 (p < 0.01 and p < 0.01, 
respectively) (Figure 4B); while in case of the PsA T lymphocytes, 
the effective cytokine combinations were TGFβ  +  IL6 and 
TGFβ  +  IL1β  +  IL6 (p  <  0.05 and p  <  0.05, respectively) 
(Figure 4C). Importantly, TBX21 mRNA was not upregulated by 
FigUre 3 | CCR6+CCR4+, CCR6+CXCR3+, and CXCR3+ chemokine receptor expression. The chemokine receptor expression of CD4+CD45RO− naive and 
CD4+CD45RO+ memory T cells were studied by flow cytometry. Healthy volunteers’ [(a) n = 6], rheumatoid arthritis (RA) [(B) n = 5], and psoriatic arthritis (PsA) 
patients’ [(c) n = 5] data. The values are shown in a linear scale; the median, minimum, and maximum values are indicated (Wilcoxon signed rank test *p < 0.05).
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any cytokine combinations used either in RA or in PsA T cells, 
while the IL1β + IL23 and IL1β + IL6 + IL23 treatments increased 
its expression of the healthy donor-derived T cells (p < 0.01 and 
p < 0.01). These data strongly suggest that the regulation of RORC 
and TBX21 expression is markedly altered in both RA and PsA.
The distribution of CCR4, CCR6, and CXCR3 chemokine 
receptor-carrying cells was studied by flow cytometry (Figure 
S4 in Supplementary Material). Although with the exception 
of TGFβ +  IL6 treatment, all cytokine combinations altered 
the proportion of the healthy CCR4 and CCR6 double positive 
cells, none of the treatments had any significant effect on the 
dispersion of the different chemokine expressing cell popula-
tions (Figure S4 in Supplementary Material). Similarly, no 
meaningful differences were found in the chemokine receptor 
expression neither in RA nor in PsA (Figure S4 in Supplementary 
Material).
characterization of il-17a and il-22 
Production
Interleukin-17A and IL-22 levels were measured by ELISA in 
cell culture media of the differentiating CD4 cells. Most treat-
ments induced a large-scale increase of the cytokine production 
(Figure  5). Supplementation of the stimulating media (CD3/
CD28/CAB) with TGFβ +  IL6 +  anti-IL4 antibody attenuated 
the IL-22 production of healthy- and PsA-derived but not those 
of the RA-derived T cells (p < 0.05 and p < 0.05, respectively) 
and the IL-17A production of the PsA T cells (p < 0.01).
Considering the potential in vivo variation of the conditions 
of Th17 differentiation (44), IL-17A and IL-22 production of the 
differentiating CD4+ T cells upon CD3/CD28/CAB stimulation, 
all cytokine and anti-IL4 treatments were compared between 
healthy donors and patient groups (Figure S5 in Supplementary 
Material). The IL-17A production pattern profoundly differed 
FigUre 4 | RORC and TBX21 expression during T-helper 17 (Th17) differentiation. Naive CD4+ T cells were differentiated toward Th17-lane. Samples were treated 
with CD3/CD28/CAB (stim) or with stim + anti-IL4 antibody and the following four cytokine combinations to promote naive CD4+ T cell differentiation: transforming 
grow factor beta (TGFβ) + IL6, TGFβ + IL6 + IL1β, IL1β + IL23, and IL1β + IL23 + IL6. Total RNA was isolated and the gene expressions were measured by 
quantitative real-time PCR on the fifth day of the differentiation. RORC and TBX21 transcription factor expressions of cells derived from healthy donors [(a) n = 10], 
rheumatoid arthritis (RA) [(B) n = 10], and psoriatic arthritis (PsA) patients [(c) n = 6] are shown in a logarithmic scale. Untreated naive cells served as controls. The 
median, minimum, and maximum values are indicated (Friedman test and pairwise Wilcoxon signed rank test *p < 0.05, **p < 0.01).
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between healthy donors versus RA (p = 0.0000026) and healthy 
donors versus PsA-derived (p = 0.0001) samples. Although the 
IL-22 production was similar in PsA and healthy (p  =  0.58) 
CD4+ T  cells, it was markedly different in RA compared to 
healthy (p  =  0.000006) groups, across treatment conditions. 
Interestingly, the RA versus PsA IL-17A pattern was rather 
FigUre 5 | Interleukin-17A (IL-17A) and IL-22 cytokine secretion during differentiation. IL-17A and IL-22 cytokine secretions were measured during T-helper 17 
differentiation of naive healthy- [(a) n = 12], rheumatoid arthritis (RA)- [(B) n = 9], psoriatic arthritis (PsA) patient-derived [(c) n = 7] CD4+ T cells. Naive CD4+ cells 
were stimulated and treated with cytokines as described earlier. The IL-17A and IL-22 levels were measured by enzyme linked immunosorbent assay method. 
Untreated cells on fifth day served as controls; the data are shown in a logarithmic scale. Median, minimum, and maximum values were indicated (Friedman test and 
pairwise Wilcoxon signed rank test, *p < 0.05, **p < 0.01, and ***p < 0.001).
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similar (p = 0.85). By contrast, the IL-22 production was appar-
ently different (p = 0.001) between the two patient groups (Figure 
S5 in Supplementary Material) pointing to the different cytokine 
profile of the two diseases.
While the transcription factor expression was similar in the 
5th and 10th days of differentiation, the IL-17A and the IL-22 
secretion decreased significantly after 5 days. In addition, the pro-
portion of CCR6+CCR4+ cells increased significantly between 5th 
FigUre 6 | Correlation of inflammatory markers with chemokine receptor expression. CD4+CD45RO+ memory T cells were isolated by using magnetic separation 
and the CCR4 expression was measured by flow cytometry. Rheumatoid arthritis (RA) (n = 5) and psoriatic arthritis (PsA) patients’ (n = 5) samples were analyzed 
and correlated (Pearson correlation) to erythrocyte sedimentation rate (ESR) (a) and to C-reactive protein (CRP) (B).
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and 10th days of differentiation, upon IL1β + IL23 + IL6 + anti-
IL4 treatment both in RA and PsA, but not in healthy donors’ 
samples (data not shown).
Based on the LDA analysis, the healthy, RA, and PsA groups 
can be separated from each other with 81% discriminative power 
and the IL1β + IL23 + IL6 + anti-IL4 induced IL-22 production 
served as the determinant factor (Figure S2C in Supplementary 
Material).
laboratory and clinical Measures related 
to Th17 Differentiation
The number of CD4+CD45RO+CCR4+ lymphocytes of RA and 
PsA patients correlated strongly with the erythrocyte sedimentation 
rate (ESR) (r =  0.72, p =  0.0093) and C-reactive protein (CRP) 
(r = 0.77, p = 0.0043) (Figure 6), suggesting the proinflammatory 
role of these cells. No correlation was found between the disease 
activity, disease duration, medications used, and the baseline 
or induced TBX21 or RORC expression. The IL-22 secretion of 
differentiating T cells (upon TGFβ + IL6 + IL1β + anti-IL4 treat-
ment) from leflunomide-treated RA patients’ was higher than 
those of the non-leflunomide-treated RA patients’ (p = 0.0159; 
data not shown).
DiscUssiOn
Several lines of evidence support the crucial role of Th17-
lymphocytes in inflammatory arthropathies (10, 11, 14, 33–35, 
45–48). The main cytokines of human in vitro Th17 cell differ-
entiation were described previously (2, 22, 25–30). However, the 
optimal conditions (cytokine concentrations, combinations, and 
treatment duration) are still elusive (26, 30, 48). Although numer-
ous observations were published regarding the serum IL-17A 
levels and the frequency of Th17 cells, these data do not reflect the 
potential plasticity of the circulating naive T cells. Importantly, only 
few data have been published regarding the regulation of Th17 cell 
differentiation in inflammatory arthropathies (9, 11, 46, 48). 
Our present data confirm and extend previous observations 
regarding the role of key cytokines and transcription factors of 
the Th17 cell development in both RA and PsA (11, 48). Here, we 
show for the first time that naive CD4+CD45RO− T lymphocytes 
are predisposed to differentiate into Th17  cells (based on the 
RORC expression); in addition, the in  vitro Th17  cell develop-
ment is significantly altered in both RA and PsA (Figure S6 
in Supplementary Material). Interestingly, while the cytokine 
treatment-induced IL-17A production was profoundly different 
between RA and PsA as compared to healthy donors, the IL-22 
production was different between RA and healthy donors, but 
not between healthy donors and PsA patients (Figure S5 in 
Supplementary Material).
Although the inductive role of IL-1β, IL-21, and IL-23 cytokines 
were described in RA- and PsA-derived T cells (11), according to 
our best knowledge, the most prominent cytokine combinations 
have not been studied systematically and compared in inflam-
matory arthropaties. Similarly to earlier observations in our 
hands, anti-IL4 antibody promoted Th17 differentiation (25). The 
precise role of TGFβ in Th17 development in immune-mediated 
diseases is still questionable (26, 28, 30, 48). In accordance with 
our present data, TGFβ treatment did not increase either the IL17 
or the IL-22 secretion. Moreover, IL1β +  IL6 +  IL23 cytokine 
treatment promoted IL-17A production in both healthy donors 
and in RA and PsA patients.
Higher RORC expression of CD4+ T  cells was described in 
early RA and juvenile idiopathic arthritis but not in PsA. However, 
RORC expression of naive CD4 lymphocytes has not been inves-
tigated in these studies (11, 46). Elevated RORC and TBX21 were 
measured in synovial fluid cells from PsA patients; although gene 
expression of naive and memory subpopulations were not deter-
mined in this work (49). In contrast to RORC expression, TBX21 
expression of naive and memory T  cells strongly correlated to 
each other, indicating the independent regulation of the RORC 
in these cell types.
Human Th17  cells express chemokine receptors CCR4 and 
CCR6 (2, 24). Th22 cells express CCR4, CCR6, and CCR10; in 
addition, they produce IL-22 but not IL-17A (50, 51). Furthermore, 
Th22 cells express very low or undetectable levels of RORC and 
TBX21 while AHR plays a cardinal role in IL-22 production of 
Th22 cells (31, 50, 52). In accordance, differentiating CD4+ T cells 
11
Baricza et al. Th17-Differentiation in Rheumatoid and PsA
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 606
from the AHR agonist leflunomide-treated RA patients produced 
significantly more IL-22 than patients who underwent biological 
therapy. Furthermore, the frequency of CD4+CD45RO+CCR4+ 
lymphocytes correlated strongly with both ESR and CRP pointing 
to the potential proinflammatory role of these cells, as described 
previously in lupus nephritis (53). CCR4+CXCR3+ cells repre-
sent a major population of synovial cells in PsA patients (54). 
According to our results, based mainly on the percentage of 
CCR4+CXCR3+ cells, of the healthy, RA and PsA groups could be 
discriminated from each other, pointing to the essential role of 
these cells in inflammation.
Previous data suggest that the CD4+ T cells are hyporesponsive 
for TCR/CD3 stimulation due to their activation and cytokine-
induced, decreased CD3ξ-chain expression (55–57). Our present 
data show that T  lymphocyte stimulation (CD3/CD28/CAB) 
induced both RORC and TBX21 expression, and IL-17A and 
IL-22 production in healthy donors. By contrast, in RA, none of 
the transcription factors, and in PsA, only RORC was induced 
(possibly due to the increased baseline expression), while produc-
tion of both cytokines was increased by stimulation. This sup-
ports that early activation and engagement of the naive T cells are 
associated with an altered cytokine network in both RA and PsA.
Peripheral PsA and RA might be clinically similar, although 
the pathogenesis of the two diseases are substantially different 
(58). While antibodies such as anti-cyclic citrullinated peptide 
antibody or rheumatoid factor are key players in RA, no specific 
autoantibodies were identified in PsA. Some cytokines (TNFα, 
IL-1β, IL-17A, IL-22, and IL-23) play a central role in the 
pathogenesis of both conditions and Th17  cells clearly have a 
crucial role in both diseases. The applied cytokine treatments 
cause a distinct and characteristic change in transcription fac-
tors (RORC and TBX21) and cytokine production (IL-17A and 
IL-22) of healthy donors, RA, and PsA patients (Figures 4 and 
5; Figure S5 in Supplementary Material). The complex effect 
of the cytokine combinations and their comparison of IL-17A 
and IL-22 production in RA and PsA were first described in this 
study, and these data support the different cytokine profile of the 
two diseases.
There are some limitations of our study, such as the small 
number of patients or the lack of synovial samples. Further work 
with higher number of patients are needed to study the naive 
T cells’ capacity to differentiate toward other T helper lineages as 
well, such as Th1, Th9, or Th22 (14, 59–62).
Our present data suggest in RA and PsA an early commit-
ment of CD4+ T  lymphocytes toward the Th17 lineage and 
a characteristic IL-17A and IL-22 production. These data 
may contribute to the understanding of Th17 differentiation 
both under physiological conditions and in RA and PsA. 
Further studies are needed to identify the underlying factors 
of the altered CD4+ T  cell development in inflammatory 
arthropathies.
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FigUre s1 | Flow cytometry cell gating strategies. The naive 
(CD3+CD4+CD45RO−CD45RA+CD197+), effector (CD3+CD4+CD45RO+ 
CD45RA−CD197−/Tem), and central (CD3+CD4+CD45RO+CD45RA−CD197+/
Tcm) memory T cells’ RAR-related orphan receptor gamma (RORγ) and T 
cell-specific T-box transcription factor T-bet (Tbet) transcription factor expression 
were studied. Isotype controls were indicated by blue and red shows the specific 
stainings. (a–h) and gates: R1-7: (a) SSC/FSC dot plot lymphocytes were gated 
(R1) from peripherial blood mononuclear cell (PBMC); (B) within R1 gate, CD3/
CD4 dot plot the double-positive helper T cells were also gated (R2); (c) within 
R2 gate, CD45RA+ (R3); CD45RO+ (R4); (D) within R3 gate, the cells were more 
than 98% positive for CD197 (R5); (e) within R4 gate, discrimination of effector 
(R6) and central (R7) memory cells based on CD197 expression; (F) within R5 
gate, RORγ and Tbet expression; (g) within R6 gate, RORγ and Tbet expression; 
(h) within R7 gate, RORγ and Tbet expression; Q1: Tbet positive cells; Q2: RORγ/
Tbet positive cells; Q3: RORγ positive cells. (J–M) and gates: G1-G3: (J) SSC/
FSC dot plot CD4+CD45RO− lymphocytes were gated (G1) from magnetically 
separated cells; (K) within G1 gate, C-C chemokine receptor 6 (CCR6)− (G2); 
CCR6+ (G3) cells were gated; (l) within G2 gate, CCR4 and C-X-C motif 
chemokine receptor 3 (CXCR3) expression; (M) within G3 gate, CCR4 and 
CXCR3 expression; Q1: CCR4 positive cells; Q2: CCR4/CXCR3 positive cells; 
Q3: CXCR3 positive cells I; (i,n) cell counts of different gates.
FigUre s2 | Discriminative power of the expression of transcription factors, 
chemokine receptors, and the cytokine production. Linear discriminant analysis 
based on the transcription factors (a), chemokine receptor expressions (B), and 
cytokine productions (c) in healthy, rheumatoid arthritis (RA), and psoriatic 
arthritis (PsA) groups.
FigUre s3 | CCR6+CCR4+CXCR3+, CCR4+CXCR3+, CCR4+, and CCR6+ 
chemokine receptor expression. The chemokine receptor expression of 
CD4+CD45RO− naive and CD4+CD45RO+ memory T cells were studied by flow 
cytometry. Healthy volunteers’ [(a) n = 6], rheumatoid arthritis (RA) [(B) n = 5], 
and psoriatic arthritis (PsA) patients’ [(c) n = 5] data. The values are shown in a 
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